ChemWerth has expanded its offerings to the generic industry by forming an alliance with Chengdu Shengnuo Biopharm Co. Ltd. (Shengnuo), the leading peptide development and manufacturing company located in Sichuan province in China. Under the agreement, ChemWerth has the exclusive agency for 10 peptides including Bivalirudin, Eptifibatide, Triptorelin, Exenatide, Pramlinitide, and Teriparitide.
Shengnuo, founded in 2003, recently commissioned a new state-of-the-art facility in 2011 for commercial manufacturing of cGMP quality peptides. ChemWerth’s CEO Peter Werth says, “the alliance with Shengnuo allows ChemWerth to tap into the large molecule market, which has become increasing important in the pharmaceutical arena.” Jeff Bauer, ChemWerth’s President, further remarks, “with more than 60 peptides currently marketed worldwide and an estimated 140 others are in clinical development, quality peptide manufacturing will be an essential component in future generic development.”
ChemWerth will provide its regulatory and quality oversight to get Shengnuo’s new facility FDA inspected. ChemWerth assisted 12 API factories worldwide (10 in China) to pass an FDA inspection in 2011 (Generic Bulletin – ###). Shengnuo President Wen Yongjun says, “ChemWerth is well known for providing regulatory, cGMP compliance support and sales access to the regulated markets for Chinese factories. Shengnuo has long been looking forward to cooperating with ChemWerth and is very pleased to have the opportunity to partner with ChemWerth and expects both companies develop better and better through the alliance.”